Kura outlines up to $300M Oberland funding and plans ~40-patient darlifarnib registrational study in 1H 2027

• "KOMZIFTI net product revenue reached $13.9 million, up 53% sequentially, while new patient starts increased 30%." (Chairman, CEO & President Troy Wilson)
• "We maintained the majority share of menin inhibitor

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.